In partnership with the American Society of Clinical Oncology including University of Colorado Cancer Center researchers, and the College of American Pathologists, Palo Alto tech company CollabRx recently released an app that matches the genetics, disease history and demographics of colorectal cancer patients to drug and clinical trial treatment options.
“This online and freely accessible tool will support and enable patient empowerment, engagement and participation in discussing and creating a personalized cancer treatment plan that leverages the unique aspects of a patient’s medical history and tumor genetic profile whenever possible,” said Wells Messersmith, MD, co-leader of the Developmental Therapeutics Program at the University of Colorado Cancer Center, and a clinical advisor to the Therapy Finder – Colorectal Cancer app.
Colorectal cancer is the 3rd most common human malignancy and the 3rd leading cause for cancer-related deaths for both men and women in the western world. It affects approximately 150,000 individuals each year in the United States alone.
Recent colorectal cancer research has identified biomarkers that allow doctors to define the cancer’s subtype. Taking into account these genetic mutation biomarkers as well as the cancer’s stage, treatment history, and sites of metastasis, the app provides personalized therapy-related options based on peer-reviewed medical and scientific literature; for example, drug recommendations, suggestions for further diagnostics, and relevant clinical trials
Messersmith and the app designers hope patients and physicians will use the information presented to stimulate discussion of optimal treatment-related choices.